Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster

被引:34
|
作者
Wilhelm, Ilca Ricarda [1 ]
Tzabazis, Alexander [1 ]
Likar, Rudolf [2 ]
Sittl, Reinhard [1 ]
Griessinger, Norbert [1 ]
机构
[1] Univ Hosp Erlangen, Dept Anaesthesiol, D-91054 Erlangen, Germany
[2] Landeskrankenhaus Klagenfurt, Dept Anaesthesiol & Intens Care, Klagenfurt, Austria
关键词
central regional pain syndromes; lidocaine; lidoderm; local anaesthetics; peripheral nervous system diseases; postherpetic neuralgia; POSTHERPETIC NEURALGIA; PATCH; 5-PERCENT; DOUBLE-BLIND; EFFICACY; TOLERABILITY; RELIEVES; SCALE;
D O I
10.1097/EJA.0b013e328330e989
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective The 5% lidocaine medicated plaster is a topical treatment for peripheral neuropathic pain symptoms (e.g. burning, shooting and stabbing pain) and is registered for the treatment of postherpetic neuralgia. This study examined the efficacy and tolerability of long-term treatment with the 5% lidocaine medicated plaster in patients with localized neuropathic pain conditions. Methods Twenty patients with localized neuropathic pain [postoperative neuropathic pain (n = 14); complex regional pain syndrome (n = 2); and postherpetic neuralgia (n = 4)], who had been successfully treated with 5% lidocaine medicated plaster, were followed up by telephone interview after 3 and 5 years. Questions were related to the efficacy, development of tolerance, tolerability, wear time and comfort of the plaster. Results At 3 years, 10 out of 20 (50%) initial responders were still using the plasters with no decline in analgesic efficacy. After 5 years, eight of the original 20 responders (40%) maintained treatment and continued to experience effective pain relief. The 12 responders who discontinued treatment did so because they no longer required analgesic therapy (n = 4); their health insurer refused to fund treatment (n = 2); they were lost to follow-up (n = 1); or had died from an illness unrelated to plaster treatment (n = 5). No patient discontinued because of inadequate analgesia or intolerable side effects. Reversible erythema occurred in two patients wearing the plaster for more than 16 h. There were no systemic side effects. Conclusion The 5% lidocaine medicated plaster provides sustained pain relief over long-term treatment in patients with neuropathic pain of various causes and is well tolerated. Eur J Anaesthesiol 27:169-173 (c) 2010 European Society of Anaesthesiology.
引用
收藏
页码:169 / 173
页数:5
相关论文
共 50 条
  • [41] Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UK
    Ritchie, Mark
    Liedgens, Hiltrud
    Nuijten, Mark
    CLINICAL DRUG INVESTIGATION, 2010, 30 (02) : 71 - 87
  • [42] Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice
    Ueberall, Michael A.
    Mueller-Schwefe, Gerhard H. H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (06) : 901 - 909
  • [43] Lidocaine 5% Medicated Plaster A Review of its Use in Postherpetic Neuralgia
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    DRUGS, 2009, 69 (15) : 2149 - 2165
  • [44] Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia (vol 28, pg 1337, 2012)
    Sabatowski, R.
    Hans, G.
    Tacken, I
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (02) : 329 - 330
  • [45] The safety and efficacy of lacosamide in the long-term treatment of diabetic neuropathic pain
    Shaibani, A
    Frye, W
    Simpson, J
    Koch, B
    NEUROLOGY, 2006, 66 (05) : A203 - A203
  • [46] Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
    Schimrigk, Sebastian
    Marziniak, Martin
    Neubauer, Christine
    Kugler, Eva Maria
    Werner, Gudrun
    Abramov-Sommariva, Dimitri
    EUROPEAN NEUROLOGY, 2017, 78 (5-6) : 320 - 329
  • [47] Duloxetine may be safe for the long-term treatment of diabetic neuropathic pain
    Ralat, JR
    Wong, S
    CNS SPECTRUMS, 2004, 9 (08) : 576 - 576
  • [48] Comparative Benefit–Risk Assessment for Lidocaine 700 mg Medicated Plaster and Pregabalin in Peripheral Neuropathic Pain Following a Structured Framework Approach
    Ingo Sabatschus
    Irmgard Bösl
    Marlou Prevoo
    Mariëlle Eerdekens
    Arne Sprünken
    Oliver Galm
    Michael Forstner
    Pain and Therapy, 2022, 11 : 73 - 91
  • [49] UTILISATION AND EXPENDITURE BEYOND HTA: A CASE STUDY OF LIDOCAINE 5% MEDICATED PLASTER
    Finnigan, K.
    Daly, M.
    Clarke, S.
    Geraghty, N.
    Barry, M.
    VALUE IN HEALTH, 2016, 19 (07) : A598 - A598
  • [50] Changing the paradigm in postherpetic neuralgia treatment: lidocaine 700 mg medicated plaster
    FORNASARI, D.
    MAGNI, A.
    PAIS, P.
    PALAO, T.
    POLATI, E.
    SANSONE, P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (10) : 3664 - 3676